Tag: upadacitinib
1. Upadacitinib combined with topical corticosteroids reduced Eczema Area and Severity Index (EASI) and Investigator’s Global Assessment for atopic dermatitis (vIGA-AD) scores significantly more than placebo with corticosteroids.
2. Efficacy of upadacitinib combination therapy was comparable to upadacitinib monotherapy, suggesting potential for steroid-sparing treatment of atopic dermatitis.
Evidence Rating Level: 1 (Excellent)
Study Rundown: For...
1. Upadacitinib combined with topical corticosteroids reduced Eczema Area and Severity Index (EASI) and Investigator’s Global Assessment for atopic dermatitis (vIGA-AD) scores significantly more than placebo with corticosteroids.
2. Efficacy of upadacitinib combination therapy was comparable to upadacitinib monotherapy, suggesting potential for steroid-sparing treatment of atopic dermatitis.
Evidence Rating Level: 1...
1. The proportion of patients with EASI ≥75% was significantly greater in the upadacitinib 30 mg and 15 mg groups than the placebo group.
2. Both upadacitinib doses were well tolerated, with the most common adverse events being acne and upper respiratory tract infection.
Evidence Rating Level: 1 (Excellent)
Study Rundown: Upadacitinib...
1. Janus kinase (JAK) inhibitor upadacitinib showed non-inferior efficacy in improving psoriatic arthritis compared to standard-of-care adalimumab.
2. High-dose upadacitinib was associated with more frequent adverse events than adalimumab.
Evidence Rating Level: 1 (Excellent)
Study Rundown: Psoriatic arthritis (PA) is an autoimmune condition primarily affecting the skin and joints. The condition is...
1. Upadacitinib was superior to abatacept in achieving remission at 12 weeks for patients with rheumatoid arthritis refractory to biologic disease-modifying antirheumatic drugs (DMARDs).
2. Upadacitinib was associated with more severe adverse events compared to abatacept.
Evidence Rating Level: 1 (Excellent)
Study Rundown: Abatacept treats rheumatoid arthritis by inhibiting T-cell proliferation and...